Drug Topics

DECEMBER 24, 2023

Vaccine approvals included two immunizations for RSV and a new pentavalent meningococcal shot.

Vaccines 196

Vaccines Immunization 196

Pharmacy Times

DECEMBER 24, 2023

From newsworthy moments to groundbreaking research, these were the most-read student-related articles on Pharmacy Times in 2023.

65

65

The Digital Apothecary

DECEMBER 24, 2023

So, 2023 is coming to a close, and 2024 is upon us soon. With that being the case, I thought I'd summarize what I have been up to and what I look forward to next year! 2023 Areas of Focus This year, my focus was largely on AI and digital health technologies (DHTs). My anticipation of the societal impact of AI, which I expressed last December, has proven accurate.

PTCE 52

PTCE 52

Med Ed 101

DECEMBER 24, 2023

The (Ambulatory Care Pharmacist) BCACP exam is changing in 2024. Pharmacists should expect a shorter exam. BPS announced that the exam will drop from 175 questions to 150 questions. When the BCACP credential was initially created, the exam was 200 questions. The 2024 BCACP content outline has remained consistent from 2023 so in general I […] The post 2024 BCACP Exam Information appeared first on Med Ed 101.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmaceutical Technology

DECEMBER 24, 2023

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Metastatic Biliary Tract Cancer.

52

52

Pharmaceutical Technology

DECEMBER 24, 2023

(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

40

40

Pharmaceutical Technology

DECEMBER 24, 2023

(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Colorectal Cancer.

40

40

Pharmaceutical Technology

DECEMBER 24, 2023

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Metastatic Biliary Tract Cancer.

52

52

Pharmaceutical Technology

DECEMBER 24, 2023

Mecbotamab vedotin is under clinical development by BioAtla and currently in Phase II for Breast Cancer.

40

40